Somatix Therapy Corp. (SOMA)
Jeffrey Casdin of Oppenheimer & Co. added the company to OpCo's Recommended List and rated it a "buy." One of SOMA's main assets, said Casdin, is probably the strongest patent estate in the field of gene therapy, covering the use of a number of different cell types, and a broad issued patent